A phase I dose-escalation study of TAK-733, an investigational oral MEK inhibitor, in patients with advanced solid tumors

Purpose TAK-733, an investigational, selective, allosteric MEK1/2 inhibitor, has demonstrated antitumor effects against multiple cancer cell lines and xenograft models. This first-in-human study investigated TAK-733 in patients with solid tumors. Methods Patients received oral TAK-733 once daily on...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Invest New Drugs
Hauptverfasser: Adjei, Alex A., LoRusso, Patricia, Ribas, Antoni, Sosman, Jeffrey A., Pavlick, Anna, Dy, Grace K., Zhou, Xiaofei, Gangolli, Esha, Kneissl, Michelle, Faucette, Stephanie, Neuwirth, Rachel, Bózon, Viviana
Format: Artigo
Sprache:Inglês
Veröffentlicht: Springer US 2016
Schlagworte:
Phase I Studies
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5306265/
https://ncbi.nlm.nih.gov/pubmed/27650277
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-016-0391-2
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge